Clinical Challenges in Diagnosis and Management of Diabetic Kidney Disease

被引:75
作者
Stanton, Robert C. [1 ]
机构
[1] Joslin Diabet Ctr, Kidney & Hypertens Div, Boston, MA 02215 USA
关键词
Diabetic kidney disease (DKD); diabetes mellitus; renal disease; prevalence; public health; BLOOD-PRESSURE CONTROL; GLOMERULAR-FILTRATION-RATE; RENIN-ANGIOTENSIN SYSTEM; STAGE RENAL-DISEASE; DIETARY-PROTEIN RESTRICTION; URINARY ALBUMIN EXCRETION; CALCIUM-CHANNEL BLOCKERS; CARDIORENAL END-POINTS; ACE-INHIBITOR; CARDIOVASCULAR OUTCOMES;
D O I
10.1053/j.ajkd.2013.10.050
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Diabetic kidney disease (DKD) is a major and increasing worldwide public health issue. There is a great need for implementing treatments that either prevent or significantly slow the progression of DKD. Although there have been significant improvements in management, the increasing numbers of patients with DKD illustrate that current management is not wholly adequate. The reasons for suboptimal management include the lack of early diagnosis, lack of aggressive interventions, and lack of understanding about which interventions are most successful. There are a number of challenges and controversies regarding the current management of patients with DKD. Understanding of these issues is needed in order to provide the best care to patients with DKD. This article describes some of the clinically important challenges associated with DKD: the current epidemiology and cost burden and the role of biopsy in the diagnosis of DKD. Treatment controversies regarding current pharmacologic and nonpharmacologic approaches are reviewed and recommendations based on the published literature are made. (C) 2014 by the National Kidney Foundation, Inc.
引用
收藏
页码:S3 / S21
页数:19
相关论文
共 134 条
[1]   Renoprotective effect of the addition of Losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic %, patients with nephropathy [J].
Abe, Hirohiko ;
Minatoguchi, Shinya ;
Ohashi, Hiroshige ;
Murata, Ichijiro ;
Minagawa, Taro ;
Okuma, Toshio ;
Yokoyama, Hitorni ;
Takatsu, Hisato ;
Takaya, Tadatake ;
Nagano, Toshihiko ;
Osumi, Yukio ;
Kakami, Masao ;
Tsukamoto, Tatsuo ;
Tanaka, Tsutornu ;
Hiei, Kunihiko ;
Fujiwara, Hisayoshi .
HYPERTENSION RESEARCH, 2007, 30 (10) :929-935
[2]   Kidney Disease and Increased Mortality Risk in Type 2 Diabetes [J].
Afkarian, Maryam ;
Sachs, Michael C. ;
Kestenbaum, Bryan ;
Hirsch, Irl B. ;
Tuttle, Katherine R. ;
Hinnmelfarb, Jonathan ;
de Boer, Ian H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (02) :302-308
[3]   Structural Renal Changes in Obesity and Diabetes [J].
Amann, Kerstin ;
Benz, Kerstin .
SEMINARS IN NEPHROLOGY, 2013, 33 (01) :23-33
[4]   Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions [J].
Angeli, Fabio ;
Reboldi, Gianpaolo ;
Mazzotta, Giovanni ;
Poltronieri, Cristina ;
Garofoli, Marta ;
Ramundo, Elisa ;
Biadetti, Alessandra ;
Verdecchia, Paolo .
CURRENT DRUG SAFETY, 2012, 7 (01) :76-85
[5]  
[Anonymous], J NEPHROL THER S2
[6]  
[Anonymous], COCHRANE DATABASE SY
[7]  
[Anonymous], PREVENTING ESRD OVER
[8]  
[Anonymous], DIABETES CARE S1
[9]  
[Anonymous], F1000 MED REP
[10]  
[Anonymous], DIAB REP CARD 2012 N